IDEA Collider: Innovation & Asymmetric Learning in Pharma

Publicly listed emails

info@ideapharma.com

Looking for the right person? Join Podseeker to find direct host and producer contacts and manage your podcast outreach.

AI-Driven Pharma Market Research: Synthetic Users - with Kwame Ferreira & Rebecca Gould.

October 07, 2026

Welcome back to the IDEA Collider podcast. In this episode, host Rick Ritacco sits down with Kwame Ferreira, Founder of Synthetic Users, and Rebecca Gould, President, Strategic Consulting & Analytics Business Unit at SAI. Together, they explore how artificial intelligence and synthetic behavioral modeling are transforming pharmaceutical market research and insight generation. For decades, market research operated under a strict constraint: you could choose two between speed, price, a...

The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution: Part II

September 14, 2026

Welcome back to the IDEA Collider podcast. In this second instalment of our future of immuno-oncology series, Alex Gray is joined by colleagues David Radwaner and Tom Brockbank to discuss what lies ahead for cancer immunotherapy. As the industry prepares for the upcoming patent expiration of Merck's dominant checkpoint inhibitor Keytruda, companies are racing to claim the next oncology backbone. We analyze the three major strategies currently shaping the pipeline: Merck’s platform defense foc...

Targeting the Totality of MS: Jason Tardio on Immunic’s Combined Neuroprotective and Anti-Inflammatory Strategy

July 16, 2026

Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Jason Tardio, President and COO of Immunic, to discuss the rapidly evolving landscape of Multiple Sclerosis (MS) treatment. For 30 years, MS therapies have primarily focused on controlling inflammation and visible relapses. Jason argues it’s time to look deeper and address the ongoing neurodegeneration driving long-term disability, known as Progression Independent of Relapse Activity (PIRA). We explore Im...

Life Science Success · Medium booking difficulty · 100 - 1,000 listeners

Raising Biotech · Medium booking difficulty · 100 - 1,000 listeners

SpreadLove In Organizations - Healthcare Leadership · Medium booking difficulty · 100 - 1,000 listeners

Moving Medicine Forward · Medium booking difficulty · 100 - 1,000 listeners

How do I get in touch with IDEA Collider: Innovation & Asymmetric Learning in Pharma?

IDEA Collider: Innovation & Asymmetric Learning in Pharma is hosted by Rick Ritacco and Alex Gray. Its publicly listed email is info@ideapharma.com. For guest bookings, the host or producer is usually the best person to reach. Podseeker helps you find direct host and producer contacts and pitch from your own inbox.

What is the email for IDEA Collider: Innovation & Asymmetric Learning in Pharma?

The publicly listed email for IDEA Collider: Innovation & Asymmetric Learning in Pharma: info@ideapharma.com.

How many listeners does IDEA Collider: Innovation & Asymmetric Learning in Pharma have?

Podseeker estimates IDEA Collider: Innovation & Asymmetric Learning in Pharma reaches 100 to 1,000 listeners per episode. Only the publisher has exact numbers.

Who is an ideal guest for IDEA Collider: Innovation & Asymmetric Learning in Pharma?

IDEA Collider: Innovation & Asymmetric Learning in Pharma typically books industry leaders. Typical guest background: Senior executives at biotechnology or pharmaceutical companies with direct expertise in drug development, clinical strategy, or healthcare innovation. Recent guests include Jason Tardio.

How hard is it to get booked on IDEA Collider: Innovation & Asymmetric Learning in Pharma?

High. It mostly books established leaders in its field.

What topics does IDEA Collider: Innovation & Asymmetric Learning in Pharma cover?

Recent episodes cover Pharmaceutical Innovation, Drug Development, Biotechnology, Life Sciences, and Healthcare. Pitch an idea tied to one of these topics and mention a recent episode.